Ayoub M, Hitier C, Dehgane L, Mallet E, et al. Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction. Leukemia 2026 Jan 7. doi: 10.1038/s41375-025-02846.
PMID: 41501504